title: [Ureteral cancer occurred in megaureter].
abstract: A 58-year-old man visited our hospital with a complaint of asymptomatic gross hematuria for three weeks. The urine cytology at another clinic had indicated Papanicolaou class V. A physical examination revealed soft abdominal distention in lower abdomen. Ultrasonography demonstrated an extremely dilated left pelvis, calyx and ureter in which a round mass was detected. Enhancement CT showed a mass 2 cm in diameter in the middle part of the dilated left ureter. These findings suggested the diagnosis of left ureteral cancer having developed in the megaureter. Neither VUR nor UVJ stenosis were identified by VCG and RP. MR-urography showed a severely dilated left pelvis and tortuous megaureter. On the diagnosis of left ureteral cancer left nephroureterectomy with cuff of bladder was performed. Gross findings showed a 2 cm sized papillary tumor in the extremely dilated ureter, and pathological findings showed grade 2, papillary transitional cell carcinoma and non-specific ureteritis in the dilated ureter. Postoperative course was non-eventful. Postoperative 3 months later multiple bladder tumors were detected all over the bladder, and so TUR-Bt and intravesical instillation therapy with pirarubisin was performed. However multiple bladder tumors had been relapsed and so finally radical cystectomy and right cutaneous ureterostomy were undergone postoperative 6 months later. He has been well 48 months postoperatively.
authors.affiliation: Department of Urology, Uji Tokushukai Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ushida
authors.forename: Yoshikata
authors.initials: Y
authors.lastname: Masuda
authors.forename: Shuichi
authors.initials: S
authors.lastname: Koizumi
authors.forename: Yusaku
authors.initials: Y
authors.lastname: Okada
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000473:pathology* / Q000601:surgery*; D003131:Combined Modality Therapy; D015653:Cystectomy; D003952:Diagnostic Imaging; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D016896:Treatment Outcome; D014513:Ureter / Q000601:surgery; D014516:Ureteral Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D014519:Ureterostomy
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; C027260:pirarubicin